12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relenza zanamivir inhaled neuraminidase inhibitor regulatory update

BTA partner GLXO withdrew its NDA for Relenza to prevent influenza A and B infection in adults. GLXO said the FDA requested additional efficacy data for the product, which GLXO plans to obtain this winter from ongoing clinical trials. GLXO previously withdrew its MAA for...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >